Drug Trial Radar · NCT06228560
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Jan 26, 2024
Primary completion
Apr 17, 2025
Study completion Oct 16, 2025
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been diagnosed with refractory CSU and who remain symptomatic despitestandard-dose H1 antihistamine treatment.
Conditions
- Chronic Spontaneous Urticaria
Interventions
LP-003Biological
Liquid in vial
PlaceboBiological
Liquid in vial
OmalizumabBiological
Liquid in vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 12Time frame: Week 12
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Wuhan NO.1 Hospital
Wuhan, China
Affiliated Hospital of Jiangsu University
Zhenjiang, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of China Medical University
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
The Second XiangYa Hospital of Central South University
Changsha, Hunan, China
Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
Nanjing, Jiangsu, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, China
the Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.